DexCom generated $4.8B in trailing twelve-month revenue, up 0.2% year-over-year. Net income was $930.4M with a 19.31% net margin. Gross margin stands at 61.5% and operating margin at 21.45%. Diluted EPS is $2.33, which grew 0.7% year-over-year. Based on the Q1 2026 filing.